Zerdapa 10 Tablet contains Dapagliflozin 10 mg, an oral antihyperglycemic agent belonging to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is primarily indicated for the management of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. Dapagliflozin acts by inhibiting SGLT2 in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering plasma glucose levels. This mechanism also contributes to modest reductions in body weight and systolic blood pressure, which may be beneficial in patients with comorbid conditions. Zerdapa 10 Tablet is typically administered once daily, with or without food, and dosage adjustments may be necessary based on renal function and tolerability. It is contraindicated in patients with severe renal impairment, end-stage renal disease, or on dialysis, as efficacy is diminished. Common adverse effects include urinary tract infections, genital mycotic infections, and increased urination. Patients should be monitored for signs of volume depletion, ketoacidosis, and hypoglycemia, especially when used in combination with insulin or insulin secretagogues. Zerdapa 10 Tablet should be used under medical supervision with regular monitoring of renal function and glycemic parameters to optimize therapeutic outcomes.